All In Biotech

Drug Trial Radar · NCT07939594

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Mar 12, 2027

Study completion Mar 12, 2027

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

Conditions

  • HIV Infections

Interventions

  • VH4011499Drug

    VH4011499 is administered to the participants based on the protocol schedule.

  • RitonavirDrug

    Ritonavir is administered to the participants based on the protocol schedule.

  • EfavirenzDrug

    Efavirenz is administered to the participants based on the protocol schedule.

  • CarbamazepineDrug

    Carbamazepine is administered to the participants based on the protocol schedule.

  • MetforminDrug

    Metformin is administered to the participants based on the protocol schedule.

  • DigoxinDrug

    Digoxin is administered to the participants based on the protocol schedule.

  • RosuvastatinDrug

    Rosuvastatin is administered to the participants based on the protocol schedule.

  • PitavastatinDrug

    Pitavastatin is administered to the participants based on the protocol schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of VH4011499 when administered aloneTime frame: Day 1 for Cohorts 1, 2 and 3
  2. Cmax of VH4011499 when co-administered with RitonavirTime frame: Day 26
  3. Cmax of VH4011499 when co-administered with EfavirenzTime frame: Day 37
  4. Cmax of VH4011499 when co-administered with CarbamazepineTime frame: Day 41
  5. Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered aloneTime frame: Day 1 for Cohorts 1, 2 and 3
  6. AUC(0-t) of VH4011499 when co-administered with RitonavirTime frame: Day 26
  7. AUC(0-t) of VH4011499 when co-administered with EfavirenzTime frame: Day 37
  8. AUC(0-t) of VH4011499 when co-administered with CarbamazepineTime frame: Day 41
  9. Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered aloneTime frame: Day 1 for Cohorts 1, 2 and 3
  10. AUC(0-inf) of VH4011499 when co-administered with RitonavirTime frame: Day 26
  11. AUC(0-inf) of VH4011499 when co-administered with EfavirenzTime frame: Day 37
  12. AUC(0-inf) of VH4011499 when co-administered with CarbamazepineTime frame: Day 41
  13. Cmax of Metformin when administered aloneTime frame: Day 1
  14. Cmax of Metformin when co-administered with VH4011499Time frame: Day 16
  15. AUC(0-t) of Metformin when administered aloneTime frame: Day 1
  16. AUC(0-t) of Metformin when co-administered with VH4011499Time frame: Day 16
  17. AUC(0-inf) of Metformin when administered aloneTime frame: Day 1
  18. AUC(0-inf) of Metformin when co-administered with VH4011499Time frame: Day 16
  19. Cmax of Digoxin when administered aloneTime frame: Day 1
  20. Cmax of Digoxin when co-administered with VH4011499Time frame: Day 16
  21. AUC(0-t) of Digoxin when administered aloneTime frame: Day 1
  22. AUC(0-t) of Digoxin when co-administered with VH4011499Time frame: Day 16
  23. AUC(0-inf) of Digoxin when administered aloneTime frame: Day 1
  24. AUC(0-inf) of Digoxin when co-administered with VH4011499Time frame: Day 16
  25. Cmax of Rosuvastatin when administered aloneTime frame: Day 5
  26. Cmax of Rosuvastatin when co-administered with VH4011499Time frame: Day 22
  27. AUC(0-t) of Rosuvastatin when administered aloneTime frame: Day 5
  28. AUC(0-t) of Rosuvastatin when co-administered with VH4011499Time frame: Day 22
  29. AUC(0-inf) of Rosuvastatin when administered aloneTime frame: Day 5
  30. AUC(0-inf) of Rosuvastatin when co-administered with VH4011499Time frame: Day 22
  31. Cmax of Pitavastatin when administered aloneTime frame: Day 1
  32. Cmax of Pitavastatin when co-administered with VH4011499Time frame: Day 17
  33. AUC(0-t) of Pitavastatin when administered aloneTime frame: Day 1
  34. AUC(0-t) of Pitavastatin when co-administered with VH4011499Time frame: Day 17
  35. AUC(0-inf) of Pitavastatin when administered aloneTime frame: Day 1
  36. AUC(0-inf) of Pitavastatin when co-administered with VH4011499Time frame: Day 17

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.